Aptose Biosciences (TSE:APS) Sets New 12-Month Low - Should You Sell?

Shares of Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$1.98 and last traded at C$2.50, with a volume of 27932 shares changing hands. The stock had previously closed at C$4.56.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners raised Aptose Biosciences to a "strong-buy" rating in a report on Thursday, February 27th.

Aptose Biosciences Price Performance

The company has a debt-to-equity ratio of -117.37, a current ratio of 1.05 and a quick ratio of 5.41. The company has a fifty day moving average of C$6.06 and a 200 day moving average of C$10.16. The firm has a market capitalization of C$206.68 million, a P/E ratio of -0.96 and a beta of 1.36.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.